Why the study?
What are the safety risks associated with anti-TNFalpha therapy in rheumatoid arthritis?
What are the safety risks associated with anti-TNFalpha therapy in rheumatoid arthritis?
This review highlights the potential safety risks of anti-TNFalpha therapy in rheumatoid arthritis, including congestive heart failure and serious infections.
May warrant monitoring for infection and HF risks with anti-TNF in RA; leaves open precise magnitude pending higher-quality data.
Anti-TNFalpha therapy may have associated risks of serious infection, congestive heart failure, malignancy, and multiple sclerosis. The magnitude of these risks is difficult to assess. This article reviews publications on the current knowledge about the safety of these agents.
No takes yet. Share an insight, caveat, or question.
Kimme L Hyrich (2004) studied this question.
Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context: